{
  "data": {
    "indicator": {
      "slug": "ctgov-glp1-trial-starts-obesity",
      "name": "GLP-1, incretin multi-agonist and amylin trial starts since 2023: Obesity or overweight",
      "definition": "Count of interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) whose conditions include obesity or overweight, started from 2023-01-01 to 2026-09-27.",
      "unit": "count",
      "scale": "1",
      "default_unit": "count",
      "default_scale": "1"
    },
    "scale": "1",
    "unit": "count",
    "region": {
      "code": "GLOBAL",
      "name": "Global",
      "type": "world"
    },
    "points": [
      {
        "period_start": "2023-01-01",
        "period_label": "1 Jan 2023 to 27 Sep 2026",
        "value": 468,
        "scale": "1",
        "unit": "count",
        "value_type": "actual",
        "statistic_id": "stat_1Z8VBW8HKC5APQSBYV82Y3HNA4",
        "url": "https://statorigin.org/stat/stat_1Z8VBW8HKC5APQSBYV82Y3HNA4",
        "source_org": "ClinicalTrials.gov",
        "source": {
          "org": "ClinicalTrials.gov (U.S. National Library of Medicine)",
          "org_short_name": "ClinicalTrials.gov",
          "document_title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) in obesity or overweight, with a start date from 2023-01-01 to 2026-09-27",
          "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&query.cond=obesity%20OR%20overweight&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL%20AND%20AREA%5BStartDate%5DRANGE%5B2023-01-01%2C2026-09-27%5D&countTotal=true&pageSize=1&fields=NCTId",
          "locator": "totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) in obesity or overweight, with a start date from 2023-01-01 to 2026-09-27.",
          "published_date": null
        }
      }
    ],
    "available_regions": [
      "GLOBAL"
    ]
  },
  "meta": {
    "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.",
    "license": "https://creativecommons.org/licenses/by/4.0/",
    "docs": "https://statorigin.org/docs/api",
    "total": 1
  }
}